 PAVmed Inc. Nasdaq: PAVM, PAVMZ the Company or PAVmed, a highly differentiated, multiproduct medical device company, today announced that its majority owned subsidiary, Lucid Diagnostics Inc. Lucid has launched its EsoGuardTM Esophageal DNA Test as a Laboratory Developed Test LDT, after completing CLIACAP certification of the test at Lucids commercial diagnostic laboratory partner ResearchDx Inc. dba Pacific Dx ResearchDx, headquartered in Irvine, CA. EsoGuard is the first such DNA test designed to facilitate the diagnosis of Barretts Esophagus BE and related precursors to highly lethal esophageal adenocarcinoma EAC. 